Skip to main content

Table 3 Comorbidities of COVID-19 patients and association with a severe disease progression based on patients from the LEOSS cohort

From: Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany

 

Overall

Patients without severe disease course

Patients with severe disease course

Crude RR1 (95% CI)

Age/Sex-adjusted RR2 (95% CI)

Participants, (n%)

6672 (100%)

5242 (78.6%)

1430 (21.4%)

  

Pulmonary comorbidities overall

15.3% (986/6460)

13.8% (703/5096)

20.7% (283/1364)

1.45 (1.30–1.63)

1.29 (1.16–1.44)

 COPD

6.9% (442/6423)

5.5% (277/5073)

12.2% (165/1350)

1.88 (1.65–2.15)

1.43 (1.25–1.63)

 Asthma

5.1% (327/6422)

5.7% (291/5068)

2.7% (36/1354)

0.51 (0.37–0.70)

0.66 (0.48–0.89)

 Other chronic pulmonary disease

4.5% (291/6409)

3.7% (186/5053)

7.7% (105/1356)

1.76 (1.50–2.07)

1.45 (1.24–1.71)

Cardiovascular comorbidities overall

59.8% (3931/6579)

55.3% (2866/5178)

76.0% (1065/1401)

2.14 (1.91–2.39)

1.30 (1.15–1.47)

 Hypertension

52.3% (3403/6501)

48.6% (2488/5124)

66.4% (915/1377)

1.80 (1.63–1.99)

1.20 (1.08–1.34)

 Myocardial infarction

6.1% (392/6421)

5.0% (256/5072)

10.1% (136/1349)

1.72 (1.49–1.99)

1.25 (1.08–1.44)

 Aortic stenosis

2.3% (145/6383)

1.9% (98/5041)

3.5% (47/1342)

1.56 (1.23–1.98)

1.03 (0.81–1.30)

 AV block

2.5% (159/6404)

2.0% (102/5062)

4.2% (57/1342)

1.74 (1.41–2.16)

1.18 (0.95–1.47)

 Carotid arterial disease

2.2% (143/6373)

1.7% (87/5038)

4.2% (56/1335)

1.91 (1.55–2.35)

1.35 (1.09–1.66)

 Chronic heart failure

9.1% (582/6383)

7.1% (359/5048)

16.7% (223/1335)

2.00 (1.78–2.24)

1.41 (1.26–1.59)

 Peripheral vascular disease

5.2% (331/6376)

4.6% (231/5042)

7.5% (100/1334)

1.48 (1.25–1.76)

1.03 (0.87–1.22)

 Atrial fibrillation

16.0% (1029/6429)

13.7% (696/5074)

24.6% (333/1355)

1.71 (1.54–1.90)

1.14 (1.02–1.27)

 Coronary artery disease

15.0% (957/6398)

12.4% (627/5051)

24.5% (330/1347)

1.84 (1.66–2.05)

1.27 (1.14–1.41)

Neurological comorbidities overall

24.4% (1509/6172)

22.3% (1080/4838)

32.2% (429/1334)

1.46 (1.33–1.62)

1.05 (0.95–1.17)

 Hemiplegia

1.6% (105/6418)

1.2% (60/5067)

3.3% (45/1351)

2.07 (1.65–2.60)

1.61 (1.28–2.05)

 Dementia

9.8% (628/6431)

7.9% (402/5076)

16.7% (226/1355)

1.85 (1.65–2.08)

1.20 (1.06–1.36)

 Cerebrovascular disease

9.3% (599/6419)

8.4% (428/5067)

12.6% (171/1352)

1.41 (1.23–1.61)

1.00 (0.87–1.15)

 Motoneuron disease

0.1% (5/6110)

0.0% (2/4810)

0.2% (3/1300)

2.82 (1.38–5.79)

1.79 (0.86–3.73)

 Movement disorder

2.9% (178/6116)

2.7% (129/4812)

3.8% (49/1304)

1.30 (1.02–1.66)

0.95 (0.75–1.21)

 Multiple Sclerosis

0.5% (32/6418)

0.6% (31/5064)

0.1% (1/1354)

0.15 (0.02–1.02)

0.24 (0.03–1.69)

 Myasthenia gravis

0.1% (6/6379)

0.0% (1/5031)

0.4% (5/1348)

3.95 (2.76–5.67)

2.63 (1.62–4.26)

 Neur. autoimmune diseases

0.2% (15/6380)

0.2% (10/5030)

0.4% (5/1350)

1.58 (0.77–3.23)

1.41 (0.77–2.56)

Oncological comorbidities overall

14.5% (938/6453)

13.2% (674/5091)

19.4% (264/1362)

1.41 (1.26–1.59)

1.15 (1.03–1.29)

 Leukemia

1.3% (84/6417)

1.1% (56/5063)

2.1% (28/1354)

1.59 (1.17–2.16)

1.52 (1.11–2.09)

 Lymphoma

1.9% (122/6417)

1.6% (81/5065)

3.0% (41/1352)

1.61 (1.25–2.08)

1.38 (1.08–1.76)

 Solid tumor

8.9% (573/6431)

8.3% (422/5077)

11.2% (151/1354)

1.28 (1.11–1.48)

0.99 (0.86–1.13)

 Solid tumor, metastasized

3.2% (205/6407)

2.8% (142/5061)

4.7% (63/1346)

1.49 (1.20–1.83)

1.38 (1.12–1.69)

 Stem cell transplant

0.4% (27/6418)

0.3% (15/5064)

0.9% (12/1354)

2.12 (1.38–3.24)

2.27 (1.53–3.38)

Diabetes

23.2% (1505/6493)

21.0% (1071/5110)

31.4% (434/1383)

1.52 (1.37–1.67)

1.25 (1.13–1.37)

Connective tissue disease

0.4% (25/6415)

0.4% (20/5063)

0.4% (5/1352)

0.95 (0.43–2.08)

1.17 (0.54–2.55)

Rheumatic disease

3.4% (217/6389)

3.2% (162/5037)

4.1% (55/1352)

1.21 (0.96–1.52)

1.13 (0.90–1.42)

Peptic ulcer disease

2.2% (139/6417)

1.9% (96/5064)

3.2% (43/1353)

1.48 (1.15–1.91)

1.20 (0.94–1.54)

Chronic liver disease

2.1% (134/6417)

1.9% (95/5063)

2.9% (39/1354)

1.39 (1.06–1.82)

1.40 (1.08–1.81)

Liver cirrhosis

1.2% (76/6415)

1.0% (51/5065)

1.9% (25/1350)

1.57 (1.14–2.18)

1.50 (1.08–2.07)

Chronic kidney disease

15.6% (1004/6420)

12.7% (645/5073)

26.7% (359/1347)

1.96 (1.77–2.17)

1.44 (1.30–1.59)

On dialysis

3.1% (196/6426)

2.4% (124/5070)

5.3% (72/1356)

1.78 (1.47–2.16)

1.46 (1.21–1.77)

Organ transplantation

1.9% (124/6422)

1.8% (91/5068)

2.4% (33/1354)

1.27 (0.94–1.71)

1.53 (1.14–2.06)

HIV

0.6% (39/6413)

0.6% (32/5064)

0.5% (7/1349)

0.85 (0.44–1.67)

1.13 (0.61–2.11)

  1. 1Univariable Poisson regression model with robust standard errors; 2Multivariable Poisson regression model with robust standard errors adjusting for age, sex at baseline. BMI body mass index, IQR interquartile range, Neur neurological
Back to article page